No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 14 of the 40 quarters in the window, leaving 26 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T13:20:45.146Z. Latest historical point 2023-05-11. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T13:20:45.146Z. Latest historical point 2023-08-10.
The latest delayed quote for Aptevo Therapeutics Inc. (APVO) stock was $1.80 as of Oct 5, 2026, 4:00 PM EDT, up 2.27% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -92.2% · 3-year avg -97.8%/yr · 5-year avg -95.3%/yr
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company primarily focused on pioneering immunotherapeutic agents for a variety of cancer treatments across the United States.
Biotechnology · Seattle, WA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2019-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 5, 2026
30 days away
EPS Estimate
-3.72
Revenue Est.
N/A
Last Quarter Results
EPS
$-5.31
vs Estimate
$-6.01
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1APVO | $3.94M | $1.80 | +2.27% | -92.21% | -95.30% | -80.35% | N/A |
| 2GRI | $4.18M | $1.91 | -2.55% | -96.44% | -95.39% | N/A | vs APVO |
| 3EOCN | $3.59M | $3.45 | -4.43% | N/A | N/A | N/A | vs APVO |
| 4AIDX | $4.32M | $0.35 | -7.26% | N/A | N/A | N/A | vs APVO |
| 5EVGN | $3.48M | $0.40 | -4.99% | -64.71% | -56.46% | -39.70% | vs APVO |
| 6ICCM | $3.47M | $1.54 | -1.91% | -94.60% | -63.05% | N/A | vs APVO |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 2 analysts
Average Price Target
$25.50
+1316.7% upside
Low
$21.00
Current
$1.80
High
$30.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-3.88 | $-3.71 | $-3.54 | 1 |
| Quarter ending Dec 2026 | $-3.60 | $-3.14 | $-2.68 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-18.06 | $-17.04 | $-16.02 | 1 |
| FY 2027 | $-10.40 | $-6.59 | $-2.78 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $7.55M | $7.55M | $7.55M | 2 |
| FY 2027 |
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| $6.74M |
| $6.74M |
| $6.74M |
| 2 |
